Ocumetics Reports Productive Meetings at ASCRS and Provides Corporate Update

Calgary, Canada — April 14, 2026 — Leads & Copy — Ocumetics Technology Corp. reported productive meetings at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, D.C., engaging with industry leaders and senior ophthalmic organization leadership.

The company also announced, at the request of the Canadian Investment Regulatory Organization (CIRO), that there is no material change in its business affairs.

Ocumetics’ discussions at ASCRS focused on clinical progress and strategic roadmap, emphasizing the success of the First-in-Human (FIH) Group 1 study, its next-generation accommodating intraocular lens design, and the beginning of patient recruitment for its FIH Group 2 study.

Key discussion areas included positive clinical outcomes and patient satisfaction in the FIH Group 1 study, the potential market impact of Ocumetics’ lens design, planning and timing for upcoming FIH Group 2 surgeries, regulatory strategy toward a U.S. FDA Investigational Device Exemption (IDE) submission, and capital requirements for clinical development and commercialization.

Dean Burns, President & CEO of Ocumetics, said the ASCRS discussions with global ophthalmology leaders were encouraging. He stated that validation of the First-In-Human Group 1 results, combined with dialogue around the regulatory and clinical pathway, reinforces the belief that Ocumetics is well positioned to advance intraocular lens technology.

Ocumetics and participating organizations have agreed to continue engagement through follow-up discussions, conducted via virtual sessions, aligned with key milestones, including the progression of additional clinical studies and advancement of regulatory filings.

Ocumetics Technology Corp. is a Canadian research and product development company dedicated to developing advanced vision correction solutions. Ocumetics aims to transform ophthalmology with intraocular lenses and vision-enhancing technologies.

Ocumetics is in the first-in-human early feasibility study phase of a technology for the ophthalmic industry, having developed an intraocular lens that fits within the eye's natural lens compartment, potentially eliminating the need for corrective lenses. It is designed to allow the eye’s natural muscle activity to shift focus, providing clear vision at all distances without glasses or contact lenses.

Source: Ocumetics Technology Corp.